AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

NEUROSCIENTIFIC BIOPHARMACEU

0.250

+0.0156.38%

Volume:566.91K

Turnover:136.94K

Market Cap:83.14M

PE:30.85

High:0.250

Open:0.240

Low:0.230

Close:0.235

Loading ...

Overview Company News Filings

NeuroScientific Biopharmaceuticals Limited's (ASX:NSB) 117% Price Boost Is Out Of Tune With Earnings

Simply Wall St.

NeuroScientific Biopharmaceuticals Begins Transfer of Manufacturing Process for Mesenchymal Stromal Cell to Q-Gen Cell Therapeutics; Shares Rise 4%

MT Newswires Live

NeuroScientific Biopharmaceuticals' (ASX:NSB) 515% return outpaced the company's earnings growth over the same one-year period

Simply Wall St.

NeuroScientific Biopharmaceuticals Appoints CEO; Shares Up 9%

MT Newswires Live

BRIEF-Neuroscientific Biopharmaceuticals Appoints Nathan Smith As CEO

NeuroScientific Biopharmaceuticals Ltd - Appoints Nathan Smith as CEO

THOMSON REUTERS

NeuroScientific Biopharmaceuticals Appoints Chief Medical Officer; Shares Up 4%

MT Newswires Live

NeuroScientific Biopharmaceuticals Ltd-DR Catherine Cole Appointed as Chief Medical Officer

THOMSON REUTERS

NeuroScientific Biopharmaceuticals Investigates Use of Stem Cell Technology on Chronic Diseases

Becoming a substantial holder-NSB.AX

Change in substantial holding-NSB.AX

Breakthrough Stem Cell Tech Acquired-StemSmart Presentation-NSB.AX

NeuroScientific Appoints Chair Following Bio-Tech Firm Acquisition; Shares Rise 4%

MT Newswires Live

ASX ALERT-StemSmart Acquisition Complete-NSB.AX

Final Director's Interest Notice x2-NSB.AX

Section 708A Notice-NSB.AX

Application for quotation of securities - NSB-NSB.AX

Results of General Meeting-NSB.AX

NeuroScientific Biopharmaceuticals Confirms Clinical Preparations for First Patient to Receive Crohn's Disease Treatment Candidate

MT Newswires Live

ASX Runners: Grand Gulf, Meteoric, Aus Strategic Materials & NeuroScientific

The Sydney Morning Herald

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NSB.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NSB.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NSB.AU\",,,,,undefined,":{"symbol":"NSB.AU","market":"AU","secType":"STK","nameCN":"NEUROSCIENTIFIC BIOPHARMACEU","latestPrice":0.25,"timestamp":1754028720000,"preClose":0.235,"halted":0,"volume":566905,"delay":0,"nameEN":"NEUROSCIENTIFIC BIOPHARMACEU","floatShares":238156864,"shares":332575706,"eps":0.008104,"marketStatus":"Market Closed","change":0.015,"latestTime":"08-01 16:12:00 AEST","open":0.24,"high":0.25,"low":0.23,"amount":136940,"amplitude":0.085106,"askPrice":0.25,"askSize":71992,"bidPrice":0.24,"bidSize":6125,"shortable":3,"etf":0,"ttmEps":0.008104,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1754265600000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.235,"openAndCloseTimeList":[[1754006400000,1754028000000]],"volumeRatio":0.5552786859950072,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NSB.AU\",,,,,undefined,":{"symbol":"NSB.AU","floatShares":238156864,"roa":"14.08%","roe":"26.99%","lyrEps":0.002243,"volumeRatio":0.5552786859950072,"shares":332575706,"dividePrice":0,"high":0.25,"amplitude":0.085106,"preClose":0.235,"low":0.23,"week52Low":0.033,"pbRate":"16.69","psRate":"37.59","week52High":0.26,"institutionHeld":0,"latestPrice":0.25,"committee":-0.843184,"eps":0.008104,"divideRate":0,"volume":566905,"delay":0,"ttmEps":0.008104,"open":0.24,"prevYearClose":0.033,"prevWeekClose":0.22,"prevMonthClose":0.235,"prevQuarterClose":0.087,"fiveDayClose":0.22,"twentyDayClose":0.14,"sixtyDayClose":0.052},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NSB.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2556841836","title":"NeuroScientific Biopharmaceuticals Limited's (ASX:NSB) 117% Price Boost Is Out Of Tune With Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2556841836","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556841836?lang=en_us&edition=fundamental","pubTime":"2025-08-02 04:40","pubTimestamp":1754080859,"startTime":"0","endTime":"0","summary":"NeuroScientific Biopharmaceuticals Limited ( ASX:NSB ) shares have continued their recent momentum with a 117% gain in...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-nsb/neuroscientific-biopharmaceuticals-shares/news/neuroscientific-biopharmaceuticals-limiteds-asxnsb-117-price","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NSB.AU"],"gpt_icon":0},{"id":"2555008711","title":"NeuroScientific Biopharmaceuticals Begins Transfer of Manufacturing Process for Mesenchymal Stromal Cell to Q-Gen Cell Therapeutics; Shares Rise 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2555008711","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555008711?lang=en_us&edition=fundamental","pubTime":"2025-07-31 13:23","pubTimestamp":1753939406,"startTime":"0","endTime":"0","summary":"NeuroScientific Biopharmaceuticals (ASX:NSB) began the transfer of its patented manufacturing process for its mesenchymal stromal cells from cell and tissue therapy at the Royal Perth Hospital in West","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","BK4539","LENZ","NSB.AU","BK4007","BK4139","BK4097","GEN","LU2286300806.USD","XAO.AU","XJO.AU","XKO.AU","BK4585","BK7067"],"gpt_icon":0},{"id":"2555833174","title":"NeuroScientific Biopharmaceuticals' (ASX:NSB) 515% return outpaced the company's earnings growth over the same one-year period","url":"https://stock-news.laohu8.com/highlight/detail?id=2555833174","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2555833174?lang=en_us&edition=fundamental","pubTime":"2025-07-31 06:24","pubTimestamp":1753914271,"startTime":"0","endTime":"0","summary":"While some are satisfied with an index fund, active investors aim to find truly magnificent investments on the stock...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-nsb/neuroscientific-biopharmaceuticals-shares/news/neuroscientific-biopharmaceuticals-asxnsb-515-return-outpace","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NSB.AU"],"gpt_icon":0},{"id":"2554204728","title":"NeuroScientific Biopharmaceuticals Appoints CEO; Shares Up 9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2554204728","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554204728?lang=en_us&edition=fundamental","pubTime":"2025-07-28 13:38","pubTimestamp":1753681139,"startTime":"0","endTime":"0","summary":"NeuroScientific Biopharmaceuticals (ASX:NSB) appointed Nathan Smith as chief executive officer, effective Monday, July 28, according to a same-day filing with the Australian bourse.The company's shares were up 9% in recent Monday trade.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XKO.AU","XJO.AU","NSB.AU","BK7067","XAO.AU"],"gpt_icon":0},{"id":"2554326744","title":"BRIEF-Neuroscientific Biopharmaceuticals Appoints Nathan Smith As CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2554326744","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554326744?lang=en_us&edition=fundamental","pubTime":"2025-07-28 09:48","pubTimestamp":1753667320,"startTime":"0","endTime":"0","summary":"BRIEF-Neuroscientific Biopharmaceuticals Appoints Nathan Smith As CEOJuly 28 (Reuters) - NeuroScientific Biopharmaceuticals Ltd NSB.AX:EXPERIENCED CELL THERAPY EXECUTIVE APPOINTED CEOAPPOINTS NATHAN SMITH AS CEOFurther company coverage: NSB.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250728:nTUE34YJVL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","NSB.AU"],"gpt_icon":0},{"id":"2554963746","title":"NeuroScientific Biopharmaceuticals Ltd -  Appoints Nathan Smith as CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2554963746","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554963746?lang=en_us&edition=fundamental","pubTime":"2025-07-28 07:19","pubTimestamp":1753658394,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250727:nTUE34YJVL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NSB.AU","BK7067"],"gpt_icon":0},{"id":"2554731471","title":"NeuroScientific Biopharmaceuticals Appoints Chief Medical Officer; Shares Up 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2554731471","media":"MT Newswires Live","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554731471?lang=en_us&edition=fundamental","pubTime":"2025-07-25 08:58","pubTimestamp":1753405112,"startTime":"0","endTime":"0","summary":"NeuroScientific Biopharmaceuticals (ASX:NSB) has appointed Catherine Cole as chief medical officer, effective immediately, according to a Friday filing with the Australian bourse.The company's shares rose 4% in recent Friday trade.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NSB.AU","BK7067","XKO.AU","XAO.AU","XJO.AU"],"gpt_icon":0},{"id":"2554364767","title":"NeuroScientific Biopharmaceuticals Ltd-DR Catherine Cole Appointed as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2554364767","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2554364767?lang=en_us&edition=fundamental","pubTime":"2025-07-25 07:19","pubTimestamp":1753399192,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250724:nTUE1XWFC1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","NSB.AU"],"gpt_icon":0},{"id":"2553293726","title":"NeuroScientific Biopharmaceuticals Investigates Use of Stem Cell Technology on Chronic Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2553293726","media":"Small Caps","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553293726?lang=en_us&edition=fundamental","pubTime":"2025-07-23 10:48","pubTimestamp":1753238937,"startTime":"0","endTime":"0","summary":"NeuroScientific Biopharmaceuticals  is investigating the use of its newly-acquired StemSmart stem cell technology for complex indications including refractory Crohn’s disease and steroid-refractory GVHD .The company recently finalised the acquisition of Isopogen WA, which developed the patented technology for the manufacture of mesenchymal stromal cells , which are derived from adult human donor bone marrow then isolated and grown in culture before the StemSmart manufacturing process is applied to improve the cells’ clinical efficacy.NeuroScientific reviewed historical studies, findings and publications prior to finalising the acquisition in an effort to determine whether other indications could benefit from StemSmart.If NeuroScientific’s SAS work is successful, the company could progress to a Phase 1/2 clinical trial.“Although the numbers are small, the positive and life-saving clinical results for adults and children with severe and life-threatening steroid-refractory GVHD supports t","market":"us","thumbnail":"https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/07/featured-1753238833726.jpg","type":0,"news_type":0,"thumbnails":["https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/07/featured-1753238833726.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://smallcaps.com.au/neuroscientific-biopharmaceuticals-stem-cell-technology-chronic-diseases/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"smallcap_stock","symbols":["NSB.AU","BK4150","MSC","BK4575","BK7067"],"gpt_icon":0},{"id":"2550162690","title":"Becoming a substantial holder-NSB.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2550162690","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550162690?lang=en_us&edition=fundamental","pubTime":"2025-07-10 13:54","pubTimestamp":1752126845,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250710:nASXrwkzr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250710:nASX2RYsp9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","NSB.AU"],"gpt_icon":0},{"id":"2548355023","title":"Change in substantial holding-NSB.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2548355023","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2548355023?lang=en_us&edition=fundamental","pubTime":"2025-07-04 12:13","pubTimestamp":1751602404,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250704:nASX6qS3SK","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250704:nASX7bFj4K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","NSB.AU"],"gpt_icon":0},{"id":"2547033436","title":"Breakthrough Stem Cell Tech Acquired-StemSmart Presentation-NSB.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2547033436","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2547033436?lang=en_us&edition=fundamental","pubTime":"2025-06-30 07:14","pubTimestamp":1751238899,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250629:nASX87PxkK","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250629:nASXbL66km:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","NSB.AU"],"gpt_icon":0},{"id":"2546619807","title":"NeuroScientific Appoints Chair Following Bio-Tech Firm Acquisition; Shares Rise 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2546619807","media":"MT Newswires Live","labels":["executive","corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546619807?lang=en_us&edition=fundamental","pubTime":"2025-06-27 10:27","pubTimestamp":1750991248,"startTime":"0","endTime":"0","summary":"NeuroScientific Biopharmaceuticals (ASX:NSB) has appointed Robert McKenzie as Non-Executive Chairman, effective Friday, June 27, following the completion of its acquisition of Isopogen WA, holder of S","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","NSB.AU"],"gpt_icon":0},{"id":"2546866750","title":"ASX ALERT-StemSmart Acquisition Complete-NSB.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2546866750","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546866750?lang=en_us&edition=fundamental","pubTime":"2025-06-27 07:29","pubTimestamp":1750980592,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250626:nASX5lGH4F","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250626:nASX48PCcx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","NSB.AU"],"gpt_icon":0},{"id":"2546757489","title":"Final Director's Interest Notice x2-NSB.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2546757489","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546757489?lang=en_us&edition=fundamental","pubTime":"2025-06-27 07:14","pubTimestamp":1750979640,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250626:nASX4X76Yb","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250626:nASX9c1wzk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","NSB.AU"],"gpt_icon":0},{"id":"2546757126","title":"Section 708A Notice-NSB.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2546757126","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546757126?lang=en_us&edition=fundamental","pubTime":"2025-06-27 07:12","pubTimestamp":1750979523,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250626:nASX5Td8S3","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250626:nASX5yyVc5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","NSB.AU"],"gpt_icon":0},{"id":"2546757557","title":"Application for quotation of securities - NSB-NSB.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2546757557","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2546757557?lang=en_us&edition=fundamental","pubTime":"2025-06-27 07:01","pubTimestamp":1750978914,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250626:nASXYJRvn","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250626:nASX5BF4lK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NSB.AU","BK7067"],"gpt_icon":0},{"id":"2545452910","title":"Results of General Meeting-NSB.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2545452910","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2545452910?lang=en_us&edition=fundamental","pubTime":"2025-06-23 09:03","pubTimestamp":1750640580,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250623:nASX9y9zlP","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250623:nASX8Yz2mX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","NSB.AU"],"gpt_icon":0},{"id":"2537290755","title":"NeuroScientific Biopharmaceuticals Confirms Clinical Preparations for First Patient to Receive Crohn's Disease Treatment Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2537290755","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2537290755?lang=en_us&edition=fundamental","pubTime":"2025-05-23 15:19","pubTimestamp":1747984753,"startTime":"0","endTime":"0","summary":"NeuroScientific Biopharmaceuticals  confirmed that the clinical preparation for the first patient to receive the first of four treatments, under the special access program in fistulising Crohn's disease, began, according to a Friday ASX filing.It said it had progressed the proposed acquisition of the StemSmart patented stem cell technology from Isopogen WA.The treatments will begin on or around June 2, with evaluation to be conducted over eight to ten weeks. Fistulas are one of the most severe complications associated with Crohn's disease and are challenging to treat, the filing noted.The first patient, along with another three patients, will together form the first cohort of patients tested under the program.Early indications from a phase two trial in refractory Crohn's disease suggest that StemSmart technology is efficacious and safe, per the filing. If the program is successful, it will progress to a phase 1/2 clinical trial.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","NSB.AU"],"gpt_icon":0},{"id":"2528976022","title":"ASX Runners: Grand Gulf, Meteoric, Aus Strategic Materials & NeuroScientific","url":"https://stock-news.laohu8.com/highlight/detail?id=2528976022","media":"The Sydney Morning Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2528976022?lang=en_us&edition=fundamental","pubTime":"2025-04-17 15:49","pubTimestamp":1744876140,"startTime":"0","endTime":"0","summary":"“Ahhhh stability” - or at least a little relative stability – was welcomed back to the markets this week.The ASX this week saw some sanity and volume return to trading with the ASX finishing up 1.3 per cent, after a Monday morning sell-off fuelled by Friday losses from the escalating China-United States trade war.Following China’s retaliatory export restrictions on rare earth elements used in defence, energy and automotives – of which China controls some 97 per cent of production for the majority – US President Donald Trump launched a probe into the need for tariffs on critical minerals this week.This week’s Bulls N’ Bears ASX Runner of the Week is…","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.smh.com.au/business/companies/asx-runners-grand-gulf-meteoric-aus-strategic-materials-and-neuroscientific-20250417-p5lsmw.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"smh_stock","symbols":["BK4585","BK4188","BK7507","ASM.AU","ARKG","BK4588","BK7067","BK7142","ASM","GGE.AU","BK7095","NSB.AU","BK4544","MEI.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":22,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NSB.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NSB.AU\",market:\"AU\",,,undefined,":[]}}